Christine P. Bump
Principal, Penn Avenue Law & Policy
Christine P. Bump is an insightful regulatory attorney with 20 years of experience developing and implementing FDA strategies for cutting-edge technology. She focuses on regulatory issues relating to devices, diagnostics, genetics and genomics, digital health, wellness, and advertising and promotion. Christine has been working on laboratory developed test (LDT) issues since 2004. She counsels laboratories, start-ups, and large corporations, and advises clients with an awareness and understanding of their business and strategic goals. Christine has prepared clinical trial and customer user agreements for laboratory and wellness products, with emphasis on patient and data privacy.
She has also developed regulatory strategies for new technologies related to IVF and pre-implantation selection, and served as dedicated counsel to a fertility clinic. Christine's policy experience includes serving as a regulatory counsel for a national coalition of diagnostic companies. She has prepared unified comments on behalf of a coalition to FDA and Congress, and prepared lobbyists for meetings on Capitol Hill regarding alternatives to existing and proposed regulations.
- Food and Drug Law
- District of Columbia
- District of Columbia Bar
-
- Georgia
-
- Vice President
- Goldbug Strategies LLC
- -
- Senior Associate
- Goodwin Procter LLP
- -
- Associate
- Hyman, Phelps & McNamara, P.C.
- -
- Emory University School of Law
- J.D. | Law
- -
-
- Emory University
- M.P.H | Health Policy and Management
- -
-
- Sweet Briar College
- B.A. | Government
- -
- Honors: Honors Degree with High Honors; summa cum laude; Phi Beta Kappa
-
- Rising Star
- SuperLawyers
- Named a Rising Star in Food & Drug Law in Washington, DC
- Dean's Public Service Award
- Emory University School of Law
- Phi Beta Kappa
- Sweet Briar College
- Presidential Medal
- Sweet Briar College
- District of Columbia Bar
- Member
- - Current
-
- State Bar of Georgia
- Member
- - Current
-
- Food & Drug Law Institute
- Member
- -
-
- Women Owned Law
- Member
- -
-
- Food & Drug Law Institute
- Editorial Advisory Board Member, Food and Drug Law Journal
- -
-
- Food & Drug Law Institute
- Member
- -
-
- Food & Drug Law Institute
- Editorial Advisory Board Member, Food and Drug Law Journal
- -
-
- Quoted in "Will President Trump Put the Kibosh on LDT Regulation?" by Jondavid Klipp
- Laboratory Economics
- "The Potential Impact of the Election on the LDT Final Rule"
- Quadax, Inc. Blog
- Quoted in "FDA Science, Vaccine Policy to Face 'Firm Hand' in Trump Return" by Nyah Phenngsitty
- Bloomberg Law
- Quoted in "Will President-Elect Donald Trump Change the FDA's LDT Final Rule?" by Scott Wallask
- Today's Clinical Lab
- Quoted in "How Do You Solve a Problem Like AI Regulation?" by Oscelle Boye, MBiomed
- G2 Intelligence Lab Industry Advisor
- Panelist, "Analyzing Specifications in the Final Rule for Lab Developed Tests", Q1 Productions Diagnostics Coverage & Reimbursement Conference, Boston, MA
- Q1 Productions
- "FDA's Quality Management System Regulation: What Laboratories Need to Know", G2 Intelligence Lab Institute Virtual Event: Advancing the Profession of Diagnostic Medicine, Virtual
- G2 Intelligence Lab Institute
- Panelist, "Impact of FDA Final Rule Regulating Lab Diagnostic Tests on Cancer Care", AVBCC 14th Annual Summit, New York City
- Association for Value-Based Cancer Care
- "Loper Bright and the Potential Impact on the Laboratory Industry", Today's Clinical Lab Webinar, Virtual
- G2 Intelligence
- "FDA's Intent to Reclassify LDTs: What it Means and What Labs Need to Know", Next Generation Dx Summit, Washington, DC
- Cambridge Analytics
- Website
- Penn Avenue Law & Policy
